Ensysce Q3 Loss of $4.52/Share Blows Past 12-Cent Consensus as Revenue Jumps 342%
ENSC sits 65% above its 52-week low of $0.23.
Summary
Ensysce posted a Q3 adjusted loss of $4.52 per share, far wider than the 12-cent loss two analysts expected and outside the -19 cent to -5 cent range. Revenue rose 342.5% to $2.18 million, beating the $1.28 million consensus, but the quarter still produced an $82.11 million net loss. The gap between the headline EPS miss and the revenue beat is the key tension here — the loss is driven by non-operating items tied to the Series C financing and Cy Biopharma deal rather than the core business, which is why revenue matters more than the EPS line. This lands hours after the 10-Q, which showed $29.7 million in cash but carried a going-concern warning with runway only into the second half of 2027. The stock is down 6.9% this quarter and 57.9% year to date, and the December 14 annual meeting vote on converting Series C preferred into roughly 358.3 million shares is the next hard event — that conversion is the dilution overhang traders are pricing.
At the time of this announcement, ENSC was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.23 to $2.17. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.